Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) AI Stock Analysis

• Market Cap: €1.20B
• Dividend Yield: N/A
• Average Volume (3M): 47.79K
• Price to Earnings (P/E): 6.1
• Beta (1Y): 0.37
• Revenue Growth: 10.26%
• EPS Growth: 6.24%
• Country: HK
• Employees: 745
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.20
• Shares Outstanding: 172,500,000
• 10 Day Avg. Volume: 34,000
• 30 Day Avg. Volume: 47,793
• PEG Ratio: 0.15
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 3.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: HK$2.50 ▲(12.61% Upside)

The overall stock score of 78 reflects the company's strong financial performance and attractive valuation. The technical analysis supports a moderately positive outlook, with the stock trading above key moving averages. The absence of earnings call data and corporate events does not impact the score significantly.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. is a biotechnology company based in Jilin Province, China, specializing in the research, development, and manufacture of pharmaceutical products. The company operates primarily in the biopharmaceutical sector, focusing on the production of high-quality biologics, including vaccines, antibodies, and other therapeutic agents. With a commitment to innovation and quality, Huinan Changlong aims to address various medical needs through its advanced biotechnological solutions.

How the Company Makes Money

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. generates revenue primarily through the sale of its biopharmaceutical products, including vaccines and therapeutic agents. The company operates on a business model that includes direct sales to healthcare providers, hospitals, and clinics. Additionally, the company may engage in partnerships with larger pharmaceutical firms for research and development collaborations, which can provide funding and resources in exchange for sharing the resulting products or technologies. Revenue is also supplemented by government contracts and grants aimed at supporting public health initiatives, particularly in vaccine development. The company’s strategic focus on innovation and compliance with regulatory standards positions it favorably within the competitive biotechnology landscape, contributing to its overall financial performance.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview

Summary

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H exhibits strong financial performance with consistent revenue and profit growth, robust margins, and a stable financial structure. The low debt-to-equity ratio and solid return on equity further enhance its financial standing. However, the decrease in free cash flow growth requires attention.

Income Statement

The company has demonstrated consistent revenue growth with a revenue growth rate of 4.7% in 2024, while maintaining strong profitability margins. Gross profit margin stands at 77.8% and net profit margin at 20.9% in 2024, reflecting efficient cost management and solid earnings. The EBIT margin of 23.7% and EBITDA margin of 26.8% further highlight strong operational performance.

Balance Sheet

The balance sheet is robust with a low debt-to-equity ratio of 0.04, indicating minimal leverage and financial risk. The company has a healthy equity ratio of 64.4%, showcasing strong equity financing. Return on equity is solid at 11.3%, indicating effective utilization of shareholder funds. The financial stability is bolstered by a significant cash reserve.

Cash Flow

The company exhibits strong cash flow generation with a free cash flow of 208.6 million. However, the free cash flow decreased by 26.6% from the previous year due to a reduction in operating cash flow. The operating cash flow to net income ratio of 1.19 indicates robust cash conversion, while the free cash flow to net income ratio of 1.13 underscores effective capital expenditure management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	926.93M	881.16M	841.54M	841.59M	705.46M	622.25M
Gross Profit	731.82M	685.25M	584.05M	648.03M	580.00M	530.74M
EBITDA	206.76M	236.33M	226.39M	231.43M	206.50M	172.92M
Net Income	182.97M	184.25M	148.21M	193.56M	143.28M	126.56M
Balance Sheet
Total Assets	2.65B	2.53B	2.32B	2.37B	2.07B	1.80B
Cash, Cash Equivalents and Short-Term Investments	748.30M	539.03M	655.59M	1.03B	262.25M	283.55M
Total Debt	72.40M	72.40M	80.40M	400.00K	400.00K	400.00K
Total Liabilities	915.73M	901.49M	838.44M	760.54M	618.56M	459.02M
Stockholders Equity	1.73B	1.63B	1.48B	1.61B	1.45B	1.35B
Cash Flow
Free Cash Flow	0.00	208.63M	284.11M	192.68M	122.25M	52.46M
Operating Cash Flow	0.00	219.65M	315.95M	203.99M	215.09M	151.23M
Investing Cash Flow	0.00	-310.93M	109.04M	-117.97M	-160.61M	-244.85M
Financing Cash Flow	0.00	-25.01M	-186.45M	-27.71M	-25.20M	-17.75M

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.22 is above the 20-day moving average (MA) of 2.16, above the 50-day MA of 2.15, and above the 200-day MA of 1.85, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.14 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8049	78 Outperform	€1.20B	6.10	11.38%	―	10.26%	6.24%
2161	75 Outperform	HK$2.43B	12.29	19.22%	7.36%	20.65%	63.21%
2348	72 Outperform	HK$1.80B	9.47	5.34%	5.38%	2.89%	-68.83%
3737	63 Neutral	HK$508.20M	22.81	1.87%	8.33%	-1.99%	-81.52%
0950	59 Neutral	HK$1.09B	11.14	5.35%	2.61%	19.80%	55.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$610.24M	―	-40.38%	―	-43.46%	-96.48%